I really liked the news too seel. This was our fir

I really liked the news too seel. This was our first trial update since 12/14 -

The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”

Comprehensive update at ASCO, no dlt observed, and PK data consistant with animal data!

There were no CTIX shares available to short through Fidelity yesterday. This PR may prompt some shorts to cover.

CTIX = Steak and lobster      CL_N = rice and beans